Citations 13
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
Sosman, Jeffrey A. , Quevedo, J. Fernando , Milhem, Mohammed , Joshua, Anthony M. , Kudchadkar, Ragini R. , Linette, Gerald P. , Lutzky, Jose , Lawson, David H. , Lao, Christopher D., Flynn, Patrick J. , Albertini, Mark R. , Sato, Takami , Lewis, Karl D. , Doyle, Austin, Ancell, Kristin Kathleen, Panageas, Katherine S. , Bluth, Mark J., Hedvat, Cyrus V. , Erinjeri, Joseph P. , Ambrosini, Grazia , Marr, Brian P. , Dickson, Mark A. , Chapman, Paul B. , Quevedo, Jorge Fernando, Carvajal, Richard D. , Gajewski, Thomas Frank , Abramson, David H. , Wolchok, Jedd D. , Schwartz, Gary K. , Milhem, Mohammed M , Lutzky, Jose
JAMA | June 17, 2014 | Volume: 311 | Issue: 23 | Pages: 2397
Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer
Wilson, Zachary C., Stauder, Michael C. , Bhatia, S., Martenson, James A., Quevedo, J. Fernando , Schomas, David A., Miller, Robert C. , Sio, Terence T.
American Journal of Clinical Oncology | May 30, 2014 | Volume: 39 | Issue: 5 | Pages: 448-452
Objectives: To determine long-term outcomes in patients with locally advanced esophageal carcinoma treated with trimodality therapy (chemoradiotherapy [CRT] and surgery, TMT) or definitive CRT. Methods: We retrospectively identified patients with advanced esophageal carcinoma treated with curative intent at our institution between 1998 and 2004. Identified patients were separated into 3 groups: patients who received TMT, patients who received CRT, and patients who began treatment with trimodality intent but did not undergo surgery (PTMT). Local control, overall survival (OS), and distant metastasis-free survival were compared using Kaplan-Meier statistics. Results: Among the 265 patients included, median follow-up was 6.4 years for surviving patients and 1.7 years for all patients. Type of esophageal cancer was adenocarcinoma in 213 patients (80%) and squamous cell carcinoma in 46 patients (17%). Treatment groups comprised 169 patients (64%) completing TMT, 46 patients medically unable to undergo surgery after neoadjuvant therapy (PTMT), and 50 (19%) who underwent CRT. Median OS was 20.5 months; actuarial 5- and 10-year OS were 27% and 12%, respectively. The TMT group had the highest 5- and 10-year OS (32% and 19%, respectively). Local control rates at 2, 5, and 10 years for all patients were 80%, 70%, and 69%, respectively. By treatment modality, 5-year local control was best (82%) for TMT, compared with 60% for CRT and 40% for PTMT groups (P<0.001). Conclusions: Patients who completed TMT had the best local control and long-term OS. In the context of TMT, surgery seemed more beneficial in patients with esophageal adenocarcinoma versus squamous cell carcinoma.
Malignant Perivascular Epithelioid Cell Tumor of the Uterus
Bleeker, Jonathan , Quevedo, J. Fernando , Folpe, Andrew L.
Rare Tumors | March 26, 2012 | Volume: 4 | Issue: 1 | Pages: 45-48
Perivascular epithelioid cell tumors (PEComas) are a rare collection of tumors arising in a wide array of anatomic locations and characterized by a myomelanocytic phenotype. PEComas which occur in non-classic anatomic distributions are known as perivascular epithelioid cell tumor-not otherwise specified (PEComa-NOS), and one of the most common primary sites for PEComa-NOS is the uterus. The risk of aggressive behavior of these tumors has been linked to a number of factors evaluable on pathologic review following initial surgical resection. We report a case of PEComa-NOS of the uterus with multiple high-risk features, including frank vascular invasion, with no evidence of recurrent disease 18 months following initial surgical resection.